Clinical development
What the published trials reported about adverse events with eloralintide, set out with the study each figure comes from. This is a record of trial findings, not medical advice.
Phase I, single dose
In the first-in-human study of 48 healthy participants, no serious adverse events occurred. Seventeen treatment-emergent events were reported across 10 participants. Only two of the 36 participants given eloralintide had a gastrointestinal event, both at the 12 mg dose, including one case of moderate vomiting.
[Verified V-04] Confirmed against the full text of Briere et al. 2025 (2026-09-18).
Phase I, 12 weeks of weekly doses
In the 100-participant multiple-ascending-dose study, 59 participants reported at least one treatment-emergent event. Those occurring in 10% or more of participants were decreased appetite (19.2%), headache (12.3%), COVID-19 (11.0%) and fatigue (11.0%). Gastrointestinal events were concentrated in the groups given larger amounts, for example nausea in 13% at 6 mg and 8.3% at 12 mg, and diarrhoea in 11.1% at 12 mg. Two serious events occurred, one in the placebo group and one in the 6 mg group, both judged unrelated to eloralintide, and there were no deaths. Thirteen participants stopped because of an adverse event, 11 on eloralintide and 2 on placebo.
[Verified V-05] Confirmed against the full text of Bhattachar et al. 2026 (2026-09-18).
Phase II, 48 weeks
In the 263-participant trial, nausea was reported by 14% on placebo against 11% (1 mg), 13% (3 mg), 64% (6 mg), 33% (9 mg), 54% (6 to 9 mg escalation) and 25% (3 to 6 to 9 mg escalation). Fatigue was 12% on placebo against 0%, 13%, 29%, 43%, 46% and 21% in the same groups. The groups were small, which is part of why the 6 mg figure is higher than the 9 mg figure. Lilly described the most common events as mild to moderate gastrointestinal symptoms and fatigue, more frequent at higher doses and less frequent with slower escalation.
[Verified V-10] Rates by arm confirmed against the PubMed abstract of Billings et al. (PMID 41207310) on 2026-09-20. Discontinuation and serious-event counts by arm are not in the free abstract and are not reported here.
Phase II, with tirzepatide
In the 367-participant EloraTZP study in adults with type 2 diabetes, Lilly reported that stopping treatment because of adverse events ranged from 10.8% to 27.0% across the combination arms and 0% to 10.8% across the eloralintide-alone arms, against 2.9% with tirzepatide alone and 16.7% with placebo. The placebo figure is higher than the tirzepatide figure, so these rates are not a clean ranking. Lilly said events were mostly gastrointestinal, generally mild or moderate and mainly during dose escalation, and more frequent in the combination arms.
[Verified V-35] Sponsor announcement of 2026-09-30, read directly on 2026-10-01. Not peer reviewed; no confidence intervals given.
Other findings reviewers have noted
A 2026 literature review notes that early studies suggest eloralintide lowers pulse rate, in contrast to the rise in heart rate seen with GLP-1 receptor agonists, but stresses that the evidence is small and short and that no amylin receptor agonist has had a dedicated cardiovascular outcomes trial. A 2026 network meta-analysis found that gastrointestinal events were more common with high-dose amylin-based therapies, based on sparse, low-certainty data.
[Verified V-50] Cardiology in Review review, abstract read 2026-10-01 and again 2026-10-02. Network meta-analysis (Endocrinology, Diabetes and Metabolism, PMID 42175595) abstract read 2026-10-02.
How to read these numbers
- Adverse event rates from different trials are not comparable, because the protocols collect and count events differently.
- Placebo groups also report nausea and fatigue, which is why each figure is shown beside its placebo rate.
- A trial adverse-event table describes a group, not what any one person will experience.
- Nothing on this page is advice on whether to take or avoid any medicine. Anyone enrolled in a trial should speak to that trial’s own team.
Related
Full efficacy and design detail is on the Phase II page and the Phase I page. For why amylin-based medicines cause nausea, see what is amylin.